Commentary on the MID3 Good Practices Paper-Reference-Cited by-同舟云学术

Commentary on the MID3 Good Practices Paper

Published:2017-07 Issue:7 Volume:6 Page:416-417
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Manolis Efthymios¹²,Brogren Jacob²³,Cole Susan²⁴,Hay Justin L.²⁴,Nordmark Anna²³,Karlsson Kristin E.²³,Lentz Frederike²⁵,Benda Norbert²⁵,Wangorsch Gaby²⁶,Pons Gerard²⁷,Zhao Wei²⁸⁹,Gigante Valeria²¹⁰,Serone Francesca²¹⁰,Standing Joseph F.²¹¹,Dokoumetzidis Aris²¹²,Vakkilainen Juha²¹³,van den Heuvel Michiel²¹⁴,Mangas Sanjuan Victor²¹⁵,Taminiau Johannes²¹⁶,Kerwash Essam²⁴,Khan David²³,Musuamba Flora Tshinanu²¹⁷,Skottheim Rusten Ine²¹⁸,

Affiliation:

1. European Medicines Agency; London UK

2. EMA Modelling and Simulation Working Group

3. Medical Products Agency; Uppsala Sweden

4. Medicines & Healthcare Products Regulatory Agency; London UK

5. Federal Institute for Drugs and Medical Devices; Bonn Germany

6. Paul Ehrlich Institute; Langen (Hessen) Germany

7. University Paris-Descartes; Paris France

8. Robert Debre University Hospital of Paris; France

9. Shandong University; Jinan China

10. Italian Medicines Agency; Rome Italy

11. University College London; UK

12. University of Athens; Greece

13. Finnish Medicines Agency; Helsinki Finland

14. Medicines Evaluation Board; Utrecht Netherlands

15. University of Valencia; Valencia Spain

16. Antwerp University Hospital; Antwerp Netherlands

17. Federal Agency for Medicines and Health Products; Brussels Belgium

18. The Norwegian Medicines Agency; Oslo Norway

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Reference9 articles.

1. Good practices in model-informed drug discovery and development: Practice, application, and documentation;EFPIA MID3 Workgroup;CPT Pharmacometrics Syst. Pharmacol.,2016

2. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance;Byon;CPT Pharmacometrics Syst. Pharmacol.

3. Reporting guidelines for population pharmacokinetic analyses;Dykstra;J. Pharmacokinet. Pharmacodyn.,2015

4. Establishing good practices for exposure-response analysis of clinical endpoints in drug development;Overgaard;CPT Pharmacometrics Syst. Pharmacol.,2015

5. Model Evaluation Group of the International Society of Pharmacometrics ISoP Best Practice Committee. Model evaluation of continuous data pharmacometric models: Metrics and graphics;Nguyen;CPT Pharmacometrics Syst. Pharmacol.,2016

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AI in Predictive Toxicology;Advances in Medical Technologies and Clinical Practice;2024-09-27

2. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers;European Journal of Pharmaceutics and Biopharmaceutics;2024-06

3. An industry perspective on current QSP trends in drug development;Journal of Pharmacokinetics and Pharmacodynamics;2024-03-05

4. Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK®;Computer Methods and Programs in Biomedicine;2024-01

5. Model‐Informed Drug Development: Steps Toward Harmonized Guidance;Clinical Pharmacology & Therapeutics;2023-08-03